1.The Patterns of Personality and Anger Expression in the Patients with Colorectal Cancer.
Sung En SOHN ; Hee Jung YOO ; Byung Sun SUH ; Jin Cheon KIM ; Oh Su HAN
Journal of Korean Neuropsychiatric Association 2000;39(3):507-515
OBJECTIVES: Although previous studies have suggested that Type 1 or Type C personality may be associated with the development of cancer, the results have not been consistent. There have been some evidences that repression, denial, or non-expression of anger are related with the incidence of colorectal cancer. However, according to the results of recent researches, aggressive hostility was related to the development of colorectal cancer. This study attempted to delineate psychological characteristics or personality patterns of the patients with colorectal cancer based on multidemensions of anger and Type 1 personality for cancer development. METHOD: The subjects were composed of 35 patients with colorectal cancer and 37 normal controls. Grossarth-Maticek personality questionnaire and the Spielberger state-trait anger expression inventory were administered. RESULTS: In comparison with the normal control group, the colorectal cancer patient group showed significantly higher scores on anger experience, angry temperament and state anger but no significant differences on Type 1 personality scale and other subscales. In the discriminant analysis patients and control groups were classified by means of state anger, angry temperament, angry reaction, anger-in, anger-out and anger control variables. When angry temperament variable was selected as a discriminant variable, 65.8% of cases had been correctly classified. CONCLUSIONS: These results suggested the relationship between the disposition to experience and express anger without particular provocation and the development of cancer.
Anger*
;
Colorectal Neoplasms*
;
Denial (Psychology)
;
Hostility
;
Humans
;
Incidence
;
Surveys and Questionnaires
;
Repression, Psychology
;
Temperament
2.The National Status of Tuberculosis Using Nationwide Medical Records Survey of Patients with Tuberculosis in Korea.
Yoon Sung PARK ; Sung Jin HONG ; Yoo Kyung BOO ; Eun Suk HWANG ; Hyun Jung KIM ; Seung Hee CHO ; Kyung In NA ; En Hi CHO ; Sang Sook SHIN
Tuberculosis and Respiratory Diseases 2012;73(1):48-55
BACKGROUND: The epidemiology of tuberculosis (TB) has been assessed based on the data of the analysis of TB patients notified to the surveillance system in Korea. However, the national status of TB is not validated through this surveillance system. The objective is to determine the epidemiology of TB and to understand the accurate status of TB patients treated in private institutions. METHODS: Medical records of 53,579 patients who had been diagnosed with TB in 2008 were analyzed. RESULTS: Among 53,579 patients, the number of sputum smear positive cases was 15,639(29.2%) and the number of new cases was 39,191 (73.1%). The drug resistance rate of new cases was 5.3%, while the rate stood at 13.3% for TB patients with treatment history. The number of multi-drug resistant TB (MDR-TB) patients was 2,472 (4.6%), which consists of 2.9% of new cases and 9.3% of TB patients with prior treatment history. The number of extensively drug-resistant TB patients was 749 (1.4%), consisting of 1.1% of new cases and 2.2% of TB patients with prior treatment history. In terms of treatment outcomes, 66.4% of all TB patients, 70.5% of new cases, 64.4% of relapse cases, and 46.8% of MDR-TB cases were cured or completed. It was inferred that in 2008, the total number of TB patients reached 70,767, 145.6 per 100,000 people (95% confidence interval, 145.5~145.7). CONCLUSION: We conclude that the medical records review of the Health Insurance Review and Assessment Service (HIRA) data can be very effective in promoting the understanding of the current status of TB in private institutions.
Data Collection
;
Disease Notification
;
Drug Resistance
;
Humans
;
Insurance, Health
;
Korea
;
Medical Records
;
Recurrence
;
Sputum
;
Tuberculosis
;
Tuberculosis, Multidrug-Resistant
3.The National Status of Tuberculosis Using Nationwide Medical Records Survey of Patients with Tuberculosis in Korea.
Yoon Sung PARK ; Sung Jin HONG ; Yoo Kyung BOO ; Eun Suk HWANG ; Hyun Jung KIM ; Seung Hee CHO ; Kyung In NA ; En Hi CHO ; Sang Sook SHIN
Tuberculosis and Respiratory Diseases 2012;73(1):48-55
BACKGROUND: The epidemiology of tuberculosis (TB) has been assessed based on the data of the analysis of TB patients notified to the surveillance system in Korea. However, the national status of TB is not validated through this surveillance system. The objective is to determine the epidemiology of TB and to understand the accurate status of TB patients treated in private institutions. METHODS: Medical records of 53,579 patients who had been diagnosed with TB in 2008 were analyzed. RESULTS: Among 53,579 patients, the number of sputum smear positive cases was 15,639(29.2%) and the number of new cases was 39,191 (73.1%). The drug resistance rate of new cases was 5.3%, while the rate stood at 13.3% for TB patients with treatment history. The number of multi-drug resistant TB (MDR-TB) patients was 2,472 (4.6%), which consists of 2.9% of new cases and 9.3% of TB patients with prior treatment history. The number of extensively drug-resistant TB patients was 749 (1.4%), consisting of 1.1% of new cases and 2.2% of TB patients with prior treatment history. In terms of treatment outcomes, 66.4% of all TB patients, 70.5% of new cases, 64.4% of relapse cases, and 46.8% of MDR-TB cases were cured or completed. It was inferred that in 2008, the total number of TB patients reached 70,767, 145.6 per 100,000 people (95% confidence interval, 145.5~145.7). CONCLUSION: We conclude that the medical records review of the Health Insurance Review and Assessment Service (HIRA) data can be very effective in promoting the understanding of the current status of TB in private institutions.
Data Collection
;
Disease Notification
;
Drug Resistance
;
Humans
;
Insurance, Health
;
Korea
;
Medical Records
;
Recurrence
;
Sputum
;
Tuberculosis
;
Tuberculosis, Multidrug-Resistant
4.KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis.
Eui Yeun YI ; Shi Young PARK ; Hyun Seok SONG ; Myung Jin SON ; Kyu Yang YI ; Sung En YOO ; Yung Jin KIM
Experimental & Molecular Medicine 2006;38(5):502-508
Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angiogenesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new benzopyran derivative, has anti-angiogenic activities. KR-31831 inhibited the proliferation, migration, invasion and tube formation of bovine aortic endothelial cells (BAECs), and suppressed the release of matrix metalloproteinase-2 (MMP-2) of BAECs. KR-31831 also inhibited in vivo angiogenesis in mouse Matrigel plug assay. Furthermore, the mRNA expressions of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor-2 (FGFR-2), and vascular endothelial growth factor receptor-2 (VEGFR-2) were decreased by KR-31831. Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers.
Vascular Endothelial Growth Factor Receptor-2/metabolism
;
Receptor, Fibroblast Growth Factor, Type 2/metabolism
;
Neovascularization, Physiologic/drug effects
;
Neovascularization, Pathologic/*drug therapy
;
Models, Biological
;
Mice, Inbred C57BL
;
Mice
;
Matrix Metalloproteinase 2/metabolism
;
Male
;
Ischemia/drug therapy
;
Imidazoles/*pharmacology/therapeutic use
;
Fibroblast Growth Factor 2/metabolism
;
Endothelial Cells/drug effects
;
Cells, Cultured
;
Cell Movement/drug effects
;
Cattle
;
Benzopyrans/*pharmacology/therapeutic use
;
Animals
;
Angiogenesis Inhibitors/*pharmacology/therapeutic use
5.A Case of Kallmann's Syndrome with Unilateral Renal Aplasia and Diabetes Mellitus.
En Jung LEE ; Sung Wook HONG ; Yun Ki HONG ; Ji Sung YOON ; Ji O MOK ; Yeo Joo KIM ; Hyeong Kyu PARK ; Chul Hee KIM ; Sang Jin KIM ; Dong Won BYUN ; Won Kyung BAE ; Kyo Il SUH ; Myung Hi YOO
Journal of Korean Society of Endocrinology 2005;20(1):96-102
Kallmann's syndrome is defined as the combination of hypogonadotropic hypogonadism and anosmia/hyposmia. The syndrome is a result of defect in the embryonic migratory pathway of gonadotropin-releasing hormone, which synthesizes neurons and olfactory axons. The hypogonadotropic hypogonadism results due to absence of or incomplete pubertal development and may be associated with anosmia, hyposmia, midline defect(color blindness, cleft-lip, cleft-palate, unilateral renal agenesis, sensorineural deafness), cryptorchidism and skeletal anomaly. Till date in Korea, few cases of Kallmann's syndrome have been reported but there are no available reports on cases of Kallmann's syndrome with unilateral renal aplasia and diabetes mellitus. We handled a case of Kallmann's syndrome associated with unilateral renal agenesis and diabetes mellitus. In the current work, we present a peculiar case as afore mentioned with the review of related literature.
Axons
;
Blindness
;
Cryptorchidism
;
Diabetes Mellitus*
;
Gonadotropin-Releasing Hormone
;
Hypogonadism
;
Kallmann Syndrome*
;
Korea
;
Male
;
Neurons
;
Olfaction Disorders
6.Construction of hNGF-betarecombinant adenovirus and screening of its expression after transfection into various cell lines
En Feng GAO ; Hun Jong CHUNG ; Kang Min AHN ; Yoon Tae KIM ; Hee Jung PARK ; Mi Ae SUNG ; Nam Yeol KIM ; Sang Bae YOO ; Hoon MYOUNG ; Soon Jung HWANG ; Myung Jin KIM ; Sung Min KIM ; Jeong Won JANG ; Jong Ho LEE
Journal of the Korean Association of Maxillofacial Plastic and Reconstructive Surgeons 2005;27(5):446-456
7.Evaluation of Xerostomia Following Intensity Modulated Radiotherapy (IMRT) for Head and Neck Cancer Patients.
Seok Ho LEE ; Tae Hyun KIM ; Eui Kyu CHIE ; Hyun Shil IM ; En Shil IM ; Jun Sun RYU ; Yoo Seok JUNG ; Sung Yong PARK ; Joo Young KIM ; Hong Ryull PYO ; Kyung Hwan SHIN ; Dae Yong KIM ; Kwan Ho CHO
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2004;22(2):106-114
PURPOSE: This study was done to evaluate xerostomia following intensity modulated radiotherapy for patients with head and neck cancer, and to analyze the correlation between the dosimetric parameters and xerostomia parameters. MATERIALS AND MEHTODS: From February till October 2003, 13 patients with 3 months of follow-up were evaluated for xerostomia after being treated for head and neck cancer with IMRT. Their median age was 57 years (range: 43~77). Xerostomia were assessed with a 4-question xerostomia questionnaire score (XQS) and a test for salivary flow rates (unstimulated and stimulated). The patients were also given a validated LENT SOMA scale (LSC) questionnaire. The evaluations were completed before radiation therapy (pre-RT) and at 1 and, 3 months after radiation therapy (RT). We evaluated xerostomia at pre-RT, 1 and, 3 months after RT. The association between the xerostomia parameters (XQS and LSC) and salivary flow rates (unstimulated and stimulated: USFR and SSFR) was assessed at 1 and 3 months after RT. RESULTS: All 13 patients showed no significant changes in XQS, LSC and Salivary Flow rates. As a result, we couldn`t find out about xerostomia development. Based on the total mean parotid dose, 3,500 cGy, we divided these patients into two groups. The 8 patients (<3,500 cGy) showed no significant changes in XQS, LSC and Salivary Flow rates. However, in 5 patients (> or =3,500 cGy), there was a significant increase in USFR and, SSFR at 3 months after RT, and for the XQS and, LSC at 1 and 3 months after RT. The correlation between XQS and, LSC, and USFR and, SSFR in all patients (13) was significant at 3 months after RT. The correlation had a tendency to the decrease for USFR and, SSFR in proportion to the increase of XQS and, LSC. CONCLUSION: Based on the results of this study, IMRT seem to be an effective treatment to significantly decrease the xerostomia. XQS and, LSC seem to be a effective tool for predicting the xerostomia. A total parotid gland mean dose of <3,500 cGy should be a planning goal if substantial sparing of the gland function is desired. Furthermore, patients should be enrolled in a study to define a more accurate threshold dose for the parotid gland.
Carisoprodol
;
Follow-Up Studies
;
Head and Neck Neoplasms*
;
Head*
;
Humans
;
Parotid Gland
;
Surveys and Questionnaires
;
Radiotherapy*
;
Xerostomia*